timothy sykes logo
NTLA Stock Slips As $150M Equity Offering Raises Dilution Fears Thumbnail
G Google News

NTLA Stock Slips As $150M Equity Offering Raises Dilution Fears

JACK KELLOGG•UPDATED APR. 29, 2026, 9:18 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Intellia Therapeutics Inc. stocks have been trading down by -9.77 percent following negative sentiment over its latest gene-editing trial data

Candlestick Chart

Live Update At 09:18:16 EDT: On Wednesday, April 29, 2026 Intellia Therapeutics Inc. stock [NASDAQ: NTLA] is trending down by -9.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

NTLA has been grinding lower over the past couple of weeks, and the chart reflects that pressure. On 2026/04/22 the stock closed at $16.57. By 2026/04/28, it finished around $13.20 after a volatile range between $12.72 and $14.16. For active traders, that’s a sharp drawdown in a short window, right as dilution headlines hit.

Intraday, NTLA has been choppy in the premarket, with prints around $13.20 earlier and then heavy trading sub‑$12 as the offering overhang weighs on sentiment. This type of tight, noisy range often shows indecision while funds and short‑term traders reposition around a deal.

Fundamentally, Intellia Therapeutics is still a classic clinical‑stage biotech story: tiny revenue and big losses. The latest annual numbers show about $67.7M in revenue, but a net loss near $95.8M and EBITDA deep in the red. Margins are massively negative, with return on equity worse than -40%. NTLA does have a strong balance sheet, including a current ratio above 5 and over $449.9M in cash and short‑term investments, but it burns a lot of cash. That’s why the new NTLA equity raise matters so much for trading — it extends the runway, but at the cost of more shares in the market.

Why Traders Are Watching NTLA’s Dilutive Offering

NTLA is front and center on many biotech watchlists because of one thing: a fresh $150M underwritten public offering of common stock. Intellia Therapeutics is tapping the equity market hard, and every share in that deal comes from the company itself. Jefferies, Goldman Sachs, and Citigroup are running the books, which means serious institutional distribution and a clear near‑term supply surge in NTLA shares.

For short‑term traders, that supply is the story. More stock hitting the tape usually pressures the price, especially when NTLA is already in a downtrend from the mid‑$16s to the low‑$13s. On top of the base deal, underwriters get a 30‑day option to buy up to 15% more shares. That overallotment, or “greenshoe,” lets them stabilize trading but also adds even more potential dilution. In simple terms, each existing NTLA share represents a smaller slice of the pie.

At the same time, Intellia Therapeutics is not raising this cash for fun. Management is steering the $150M toward its CRISPR‑based drug development pipeline. For longer‑term biotech specialists, that pipeline is the entire NTLA thesis. More money means more shots on goal, more trials, and more time to try to turn science into a commercial product. The problem for near‑term trading is that the benefits are far out on the horizon, while dilution hits right now.

Adding another layer, Goldman Sachs just bumped its NTLA price target from $8 to $9 but kept a Sell rating. That’s a subtle message: even after a sizeable slide and a big capital raise, one of the biggest Wall Street firms still sees downside from current levels. For many momentum and swing traders, that kind of bearish stamp often encourages more short bias or cautious sizing around NTLA.

More Breaking News

Conclusion

NTLA sits at one of those classic biotech crossroads that active traders know well. On one side, Intellia Therapeutics is shoring up its balance sheet with a $150M stock sale and a 15% overallotment option, likely boosting cash well beyond the roughly $167.6M already on hand at the last report. On the other, every dollar raised comes with real dilution, layered onto a business that generated only about $23M in recent quarterly operating revenue against nearly $121.7M in operating expenses.

The tape confirms that tension. NTLA has broken lower from the mid‑teens into the low‑teens, and the offering overhang gives shorts a clean narrative: negative earnings, steep cash burn, and now more shares. Day traders watching NTLA’s intraday action can see those tight premarket ranges and repeated failure to push meaningfully higher — a textbook sign of supply sitting above.

That said, the CRISPR angle keeps Intellia Therapeutics on radar screens. A well‑funded gene‑editing pipeline can spark sharp spikes on any positive data or partnership headlines. NTLA is exactly the kind of stock where unexpected catalysts can light up the chart.

For now, this remains a trading vehicle, not a comfort blanket. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.” In the words often repeated by Tim Sykes, “Cut losses quickly, because big losers start out as small losers.” Applied to NTLA, that means respecting the dilution, respecting the downtrend, and treating every trade as a planned campaign — not a hope trade. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading NTLA

Millionaire's
POV on NTLA

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”